Cambrex Begins $120 Million Expansion at Charles City Facility in Iowa

manufacturing-news
Image Courtesy: Pixabay

Cambrex, a global contract development and manufacturing organisation (CDMO), has marked the groundbreaking of a $120 million expansion at its manufacturing facility in Charles City, Iowa. The project will add 160,000 litres of manufacturing capacity, increasing the site’s total capacity by approximately 25% to nearly one million litres. The additional capacity will support the development and commercial manufacturing of small molecule active pharmaceutical ingredients (APIs) and synthetic peptides.

The expansion is expected to be completed in the fourth quarter of 2028. It will strengthen the facility’s ability to serve pharmaceutical customers across development and commercial manufacturing, while building on its existing infrastructure and technical capabilities.

A groundbreaking ceremony held on October 29 brought together Cambrex leaders, employees, state and local officials, and members of the Charles City community to mark the start of construction. The announcement coincides with the facility’s 100th anniversary, recognising a century of operations at the site.

” This groundbreaking marks an important milestone in our continued investment in U.S. manufacturing and in the Charles City site,” said Claudio Russolo, Chief Operating Officer and incoming Chief Executive Officer of Cambrex. “As the site celebrates its 100th anniversary, this expansion reflects both its long history and its continued importance to our future. By expanding commercial-scale capacity for both small molecule and peptide manufacturing, we are strengthening our ability to support customers as their programs advance from development through commercialization.”

The Charles City facility provides development and manufacturing services for small molecule APIs, synthetic peptides and pharmaceutical intermediates. Its capabilities support customer programmes ranging from clinical development to commercial-scale production. The new investment will expand the site’s manufacturing capacity and reinforce its role in Cambrex’s global network.

Cambrex provides drug substance development and manufacturing services across the pharmaceutical lifecycle, along with comprehensive analytical services. The company has more than 45 years of experience and employs approximately 2,000 experts serving customers across North America and Europe.

Its specialised capabilities include continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterisation, complex synthetics and highly potent APIs. The Charles City expansion adds capacity in small molecule and peptide manufacturing, enabling Cambrex to support customers as their development programmes progress towards commercial production.